Anti‐TNF‐associated cutaneous leishmaniasis: a single‐institution experience

Abstract

Leishmaniasis is an infection by protozoa Leishmania, vector‐transmitted by sandflies. There are three major forms: cutaneous (CL), mucocutaneous and visceral (VL). It is endemic on the European Mediterranean basin, where mostly Leishmania infantum produces CL. Over the last decade, cases in patients undergoing tumor necrosis factor (TNF) inhibitor (anti‐TNF) have been reported. This could result from increasingly widespread anti‐TNF use coupled with a rising global incidence¹. Notably, 80% of all reported cases are related to residence or travel to European Mediterranean countries, particularly Spain.

This article is protected by copyright. All rights reserved.

http://bit.ly/2sK6Oqx